"If the PHE were suddenly terminated, it would sow confusion and chaos into this critical wind-down," the White House said.

The model augmented and significantly improved diagnostic performance for abdominal subspecialists as well as residents—a result researchers say has major clinical implications.

The latest findings highlight the worsening crisis of burnout among U.S. clinicians, who have frequently cited the COVID-19 pandemic as a major impact.

“The use of the defective catheter may cause serious adverse health outcomes, including bleeding or the need for surgical removal and replacement of the affected catheter,” according to an FDA advisory.

The finding comes from a new expert consensus statement published by the Society for Cardiovascular Angiography and Interventions. Several industry societies, including the ACC and AHA, have endorsed the document. 

The device was first recalled in 2022, but a new software update has now been released that addresses the issue. The FDA wanted a new recall to be issued to ensure all customers went through with the update.

In March of 2022, 177Lu-PSMA-617 was approved by the U.S. Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer in men with PSMA-avid disease who have previously undergone chemotherapy and a novel androgen receptor-directed therapy. 

Has point-of-care ultrasound outpaced hospitals’ capacity to incorporate the technology without anointing any particular specialty its proper guardian? The case could be made.